Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-C-Met Antibody Onartuzumab (MetMAb) in the Second- And Third-Line Non-Small Cell Lung Cancer

AAPS Journal - United States
doi 10.1208/s12248-016-0029-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Monovalent Antibody Design and Mechanism of Action of Onartuzumab, a MET Antagonist With Anti-Tumor Activity as a Therapeutic Agent

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2013English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Aggregation of Lipid Rafts Activates C-Met and C-SRC in Non-Small Cell Lung Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Comparison of Primary Tumor SUVmax Between Small Cell Lung Cancer and Non-Small Cell Lung Cancer

Current Trends in Clinical & Medical Imaging
2019English

Tumor Evolution in Non-Small-Cell Lung Cancer

ESMO Open
Cancer ResearchOncology
2018English

Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer

Effective Pharmacotherapy
2019English

Second-Line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib

Frontiers in Medicine
Medicine
2017English

P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy